Viewing nowNelson Pregabalin Capsule 75 mg (Pregabalin)
Pregabalin 75mg
Hard capsule · Prescription medication
Korea Nelson Pharmaceutical Co., Ltd.

MFDS item code 201603532 · Approved 2016.06.16 · Insurance code 665506830
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures
This drug is used to treat peripheral and central neuropathic pain in adults and is used as an adjunctive treatment for partial seizures in epilepsy patients. It is also effective in the treatment of fibromyalgia. It helps improve symptoms related to various neurological conditions.
This medication is administered orally, regardless of food, with the total daily dose of pregabalin divided into 2 doses. Because this medication is primarily excreted by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Depending on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may then be increased at intervals of 7 days to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Depending on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’.) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Depending on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may then be increased at intervals of 7 days to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg ~ 450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and, based on efficacy and tolerability, may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys unchanged. Because the clearance of this medication is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above calculation by 0.85. This medication is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Starting dose 25, maximum dose 100, single dose b TID = Total daily dose administered in 3 divided doses BID = Total daily dose administered in 2 divided doses QD = Administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under the dosing regimen. b: Supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Older adults (aged 65 years and over) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.
This medication may cause suicidal thoughts or behavior, so if symptoms of depression or mood changes occur during treatment, you should immediately inform your healthcare professional. Patients with allergies to this drug or certain genetic conditions such as lactose intolerance should not take it. Diabetic patients may need to adjust their blood sugar control medications due to weight gain, and if symptoms of angioedema appear, they should stop taking the medication immediately. Elderly patients should be cautious due to the risk of falling due to dizziness or drowsiness, and if vision blurriness or changes occur, they should consult with their healthcare professional. Abrupt discontinuation of this medication can lead to withdrawal symptoms such as insomnia, headache, and anxiety, so it should be gradually reduced according to the physician's instructions. Patients with a history of drug abuse may have a higher risk of abuse with this medication, so they should discuss this with their healthcare professional before use. Patients with heart disease or reduced kidney function need to be cautious while taking this medication, and taking it with central nervous system depressants can increase the risk of respiratory depression. Pregnant women should avoid this medication during early pregnancy due to the risk of fetal malformations, and women of childbearing age should use effective contraception during treatment. Breastfeeding women should consult with their healthcare professional about whether to stop breastfeeding or discontinue the medication, as this drug can be transmitted through breast milk and may affect the baby. This drug can cause dizziness and drowsiness, so it is safe to avoid dangerous activities such as driving or operating machinery after taking it. In case of severe skin rashes or allergic reactions, the medication should be stopped immediately, and medical attention should be sought. In case of overdose, symptoms such as confusion, drowsiness, and seizures may occur, so the prescribed dosage must be strictly followed, and if necessary, treatments such as dialysis may be performed. This medication should be kept out of the reach of children and should not be transferred to other containers.
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a tightly sealed container to prevent air or moisture from entering. The storage temperature should be maintained between 15 degrees and 30 degrees Celsius.
A hard capsule with a reddish-brown top and white bottom containing a white powder that is white or light yellow.
30C/bottle, 60C/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Hard capsule · Prescription medication
Korea Nelson Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.